Milestone Pharmaceuticals Inc. Common Shares (MIST)
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases and acute care conditions. Founded to address unmet medical needs, the company leverages its expertise in clinical research and drug development to bring novel treatments to market. Its pipeline includes products aimed at improving patient outcomes in areas such as arrhythmias and other acute cardiovascular events.
Company News
Milestone Pharmaceuticals will present research data on etripamil, a potential treatment for paroxysmal supraventricular tachycardia, at the American Heart Association Scientific Sessions in New Orleans in November 2025.
Milestone Pharmaceuticals has initiated an underwritten public offering of common shares and warrants to raise funds for clinical development and commercial launch of etripamil, a treatment for paroxysmal supraventricular tachycardia (PSVT).
Milestone Pharmaceuticals (MIST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Analysts say these are penny stocks to buy. Do you agree? The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 992% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.